stockportfolio.pro
Stocks / AVBP vs GHRS
AVBP vs GHRS
ArriVent BioPharma, Inc. and GH Research PLC side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| ArriVent BioPharma, Inc. (AVBP) | GH Research PLC (GHRS) | |
|---|---|---|
| Market cap | $1.4B | $1.4B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-166.31M | $-48.26M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -54.1% | -17.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | — | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AVBP — free Open GHRS — freeFrequently asked questions
Which is bigger, AVBP or GHRS?
ArriVent BioPharma, Inc. is larger by market capitalization — $1.4B versus $1.4B.
Which grows faster, AVBP or GHRS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.